Quetiapine (pron.: /kwɨˈtaɪ.əpiːn/ kwi-TY-ə-peen) (branded as Seroquel, Xeroquel, Ketipinor), is an atypical antipsychotic approved for the treatment of schizophrenia, bipolar disorder, and in the XR version along with an SSRI to treat major depressive disorder.
Annual sales are approximately $5.7 billion worldwide, with $2.9 billion in the United States. The U.S. patent, which was set to expire in 2011, received a pediatric exclusivity extension which pushed its expiration to March 26, 2012. The patent has already expired in Canada. There are now several generic versions of quetiapine, such as Quepin, Syquel and Ketipinor.
Quetiapine (Seroquel) 25 mg tablets, next to US one-cent
coin for comparison.
Quetiapine fumarate is used to treat either schizophrenia or bipolar disorder.
Quetiapine is one of the most well tolerated neuroleptics of other atypical antipsychotics by reducing the incidence of extrapyramidal symptoms. In low doses (50-100 milligrams), the drug acts as a selective histamine H1 blocker as well as antagonizing the alpha-adrenoreceptors. In higher doses, quetiapine attaches to autoreceptors.
In the United States, the Food and Drug Administration (FDA) has approved quetiapine for the treatment of schizophrenia and of acute manic episodes associated with bipolar disorder (bipolar mania) and for treatment of bipolar depression. In 2009, quetiapine XR was approved as adjunctive treatment of major depressive disorder.
Quetiapine is also used off-label for aggression, Alzheimer's disease, anger management, anxiety, attention deficit hyperactivity disorder, bipolar maintenance, dementia, depression, mood disorder, post-traumatic stress disorder, suicidal ideation and sleeplessness. In April 2010, AstraZeneca settled a longstanding U. S. Department of Justice investigation into its aggressive marketing of Seroquel for such off-label uses with a $520 million dollar fine. According to the Department of Justice, "the company recruited doctors to serve as authors of articles that were ghostwritten by medical literature companies and about studies the doctors in question did not conduct. AstraZeneca then used those studies and articles as the basis for promotional messages about unapproved uses of Seroquel."
It is debatable whether, as a class, typical or atypical antipsychotics are better. Both have equal drop-out and symptom relapse rates when typicals are used at low to moderate dosages.
In those with bipolar disorder, it is used for depressive episodes, acute manic episodes associated with bipolar I disorder (as either monotherapy or adjunct therapy to lithium, valproate or lamotrigine), and maintenance treatment of bipolar I disorder (as adjunct therapy to lithium or divalproex).
Quetiapine is ineffective in reducing agitation among people with Alzheimer's, whose usage of the drug once constituted 29% of sales. Quetiapine worsens cognitive functioning in the elderly with dementia and therefore is not recommended.
It is sometimes used off-label, often as an augmentation agent, to treat conditions such as obsessive-compulsive disorder, post-traumatic stress disorder, autism, alcoholism, borderline personality disorder, Charles Bonnet Syndrome, depression, Tourette syndrome, musical hallucinations and has been used by physicians as a sedative for those with sleep disorders or anxiety disorders. Off label use is not endorsed by the manufacturer. There have been no conclusive studies on the long term side effects in off - label uses such as sleep disorders..
The most common side-effect of quetiapine is somnolence. Other common side-effects include: sluggishness, fatigue, dry mouth, sore throat, dizziness, abdominal pain, constipation, upset stomach, orthostatic hypotension, inflammation or swelling of the sinuses or pharynx, blurred vision, increased appetite, and weight gain. Hypothyroidism has been seen in up to 5% of patients with various effects on levels of TSH, T4 and T3.
Uncommon side effects include bruises, disturbance in speech and language, and/or frightening hallucinations. Mouth ulcers are a rare side effect. Very rare side effects reported were rapid swelling of the skin around the eyes, which increased the appearance of skin ageing.
There is an emerging controversy regarding quetiapine fatalities. The deaths of at least six U.S. military veterans who were given drug cocktails including quetiapine have been attributed to its inclusion by military doctors to treat PTSD. Approximately 10,000 lawsuits against AstraZeneca for problems ranging from slurred speech and chronic insomnia to death have been filed by individuals from civilian populations.
It is marketed as one of the most sedating of all anti-psychotics, although those claims are contested. Beginning users may feel extremely tired and 'out of it' for the first few days, and sometimes longer. Quetiapine's newest indication, for bipolar depression, usually specifically calls for the entire dose to be taken before bedtime due to its sedative effects. The sedative effects may disappear after some time on the drug, or with a change of dosage, and with possibly different, non-sedative side-effects emerging.
Both typical and atypical antipsychotics can cause tardive dyskinesia. According to one study, rates are lower with the atypicals at 3.9% as opposed to the typicals at 5.5%. Although Quetiapine and Clozapine are atypical antipsychotics, switching to these atypicals is an option to minimize symptoms of tardive dyskinesia caused by other atypicals.
Weight gain can be a problem for some patients. Quetiapine has been found to cause more weight gain than fluphenazine, haloperidol, loxapine, molindone, olanzapine, pimozide, risperidone, thioridazine, thiothixene, trifluoperazine, and ziprasidone, but less than chlorpromazine, clozapine, perphenazine, and sertindole when calculated according to a fixed effects model.
Studies conducted on beagles have resulted in the formation of cataracts. While there are reports of cataracts occurring in humans, controlled studies including thousands of patients have not demonstrated a clear causal association between quetiapine therapy and this side-effect. However, the Seroquel website still recommends users have eye examinations every six months.
As with some other anti-psychotics, quetiapine may lower the seizure threshold, and should be taken with caution in combination with drugs such as bupropion.
A recent comparative study of anti-psychotics drugs has found that quetiapine mono treatment was associated with increased risk of death relative to the other analyzed treatments (but still better than no anti-psychotics drug treatment at all).
Quetiapine should be discontinued gradually, with careful consideration from the prescribing doctor, to avoid withdrawal symptoms or relapse.
The British National Formulary recommends a gradual withdrawal when discontinuing anti-psychotic treatment to avoid acute withdrawal syndrome or rapid relapse. Due to compensatory changes at dopamine, serotonin, adrenergic and histamine receptor sites in the central nervous system, withdrawal symptoms can occur during abrupt or over-rapid reduction in dosage. However, despite increasing demand for safe and effective antipsychotic withdrawal protocols or dose-reduction schedules, no specific guidelines with proven safety and efficacy are currently available.
Withdrawal symptoms reported to occur after discontinuation of antipsychotics include nausea, emesis, lightheadedness, diaphoresis, dyskinesia, orthostatic hypotension, tachycardia, insomnia, nervousness, dizziness, headache, excessive non-stop crying, and anxiety. According to Eli Lilly internal documents, discontinuation of atypical neuroleptics similar to seroquel can also cause psoriasis, gingivitis and other inflammatory conditions, dyspepsia, headache, high blood sugar and other health conditions unrelated to psychiatric condition. Some have argued that additional somatic and psychiatric symptoms associated with dopaminergic super-sensitivity, including dyskinesia and acute psychosis, are common features of withdrawal in individuals treated with neuroleptics. This has led some to suggest that the withdrawal process might itself be psychosis-mimetic, producing psychotic-like symptoms even in previously healthy patients, indicating a possible pharmacological origin of mental illness in a yet unknown percentage of patients currently and previously treated with antipsychotics. This question is unresolved, and remains a highly controversial issue among professionals in the medical and mental health communities, as well the public.
Most instances of acute overdosage result only in sedation, hypotension and tachycardia, but cardiac arrythmia, coma and death have occurred in adults. Serum or plasma quetiapine concentrations are usually in the 1–10 mg/L range in overdose survivors, while postmortem blood levels of 10–25 mg/L are generally observed in fatal cases.
Pregnancy and lactation
Pregnancy risk factor C. Drug is toxic to fetus and embryo but have not shown any effect with animals. Long term exposure on infant development is still very unknown, however use in third trimester has risk for abnormal muscle movements and withdrawal symptoms. In newborns, symptoms that may occur are agitation, feeding disorder, hypertonia, hypotonia, respiratory distress, somnolence, and tremor. Hospitalization may be required. During lactation, drug enters breast milk and is not recommended to be taken.
Comparison of affinities (Ki, nM)
Quetiapine has the following pharmacological actions:
This means Quetiapine is a dopamine, serotonin, and adrenergic antagonist, and a potent antihistamine with clinically negligible anticholinergic properties. Quetiapine binds strongly to serotonin receptors,the drug acts as partial agonist at 5-HT1A receptors. Serial PET scans evaluating the D2 receptor occupancy of quetiapine have demonstrated that quetiapine very rapidly disassociates from the D2 receptor. Theoretically, this allows for normal physiological surges of dopamine to elicit normal effects in areas such as the nigrostriatal and tuberoinfundibular pathways, thus minimizing the risk of side-effects such as pseudo-parkinsonism as well as elevations in prolactin. Some of the antagonized receptors (serotonin, norepinephrine) are actually autoreceptors whose blockade tends to increase the release of neurotransmitters.
Norquetiapine is the active metabolite of quetiapine. It has most of the effects of quetiapine with similar potencies, and is also a potent norepinephrine reuptake inhibitor and muscarinic antagonist. Note that the data below is from another source (the official prescribing info for Seroquel), and the measure is different from the above (Ki vs. IC50). There are still order-of-magnitude discrepancies for D1, α1, H1 and M1.
The synthesis of quetiapine begins with a dibenzothiazepinone. The lactam is first treated with phosphoryl chloride to produce a dibenzothiazepine. A nucleophilic substitution is used to introduce the sidechain.
At very low doses quetiapine acts primarily as a histamine receptor blocker (antihistamine) and α1-adrenergic blocker. When the dose is increased quetiapine activates the adrenergic system and binds strongly to serotonin receptors and autoreceptors. At high doses quetiapine starts blocking significant amounts of dopamine receptors. Use of low-dose quetiapine (<150 mg) is not recommended except temporarily during drug titration period (less than 30 days).
Due to compensatory changes at dopamine, serotonin, adrenergic and histamine receptor sites in the central nervous system, a gradual reduction in dosage is recommended to minimise or avoid withdrawal symptoms. Withdrawal symptoms reported to occur after discontinuation of quetiapine include: insomnia, nausea, emesis, lightheadedness, diaphoresis, orthostatic hypotension, tachycardia, as well as nervousness, dizziness, headache, and anxiety. The present evidence suggests that these symptoms affect a small number of susceptible individuals treated with quetiapine.
The British National Formulary recommends a gradual withdrawal when discontinuing antipsychotic treatment to avoid acute withdrawal syndrome or rapid relapse.
AstraZeneca submitted a new drug application for a sustained-release version of quetiapine in the United States, Canada, and the European Union in the second half of 2006 for treatment of schizophrenia. AstraZeneca will retain the exclusive right to market sustained release quetiapine until 2017. The sustained-release quetiapine is marketed mainly as Seroquel XR. Other marketing names are Seroquel Prolong and Seroquel Depot.
On May 18, 2007, AstraZeneca announced that the U.S. FDA approved Seroquel XR for acute treatment of schizophrenia. During its 2007 Q2 earnings conference, AstraZeneca announced plans to launch Seroquel XR in the U.S. during August 2007. However, Seroquel XR has only become available in U.S. pharmacies after the FDA approved Seroquel XR for use as maintenance treatment for schizophrenia, in addition to acute treatment of the illness, on November 16, 2007. The company has not provided a reason for the delay of Seroquel XR's launch.
Health Canada approved sale of Seroquel XR on September 27, 2007.
The FDA approved Seroquel XR for the treatment of bipolar depression and bipolar mania in early October, 2008. According to AstraZeneca, Seroquel XR is "the first medication approved by the FDA for the once-daily acute treatment of both depressive and manic episodes associated with bipolar."
On July 31, 2008, Handa Pharmaceuticals, based in Fremont, California, announced that its abbreviated new drug application (“ANDA”) for quetiapine fumarate extended-release tablets, the generic version of AstraZeneca’s SEROQUEL XR, has been accepted by the FDA.
On December 1, 2008, Biovail announced that the FDA had accepted the company's ANDA to market its own version of sustained-release quetiapine. Biovail's sustained-release tablets will compete with AstraZeneca's Seroquel XR.
On December 24, 2008, AstraZeneca notified shareholders that the FDA had asked for additional information on the company's application to expand the use of sustained-release quetiapine for treatment of depression.
Quetiapine received its initial indication from U.S. FDA for treatment of schizophrenia in 1997. In 2004, it received its second indication for the treatment of mania-associated bipolar disorder. In 2007 and 2008, studies were conducted on quetiapine’s efficacy in treating generalized anxiety disorder and major depression. In April 2009, the Psychopharmacologic Drugs Advisory Committee of the FDA held a public meeting to discuss whether study results supported the FDA's approval for anxiety and depression, with risks of metabolic side-effects and of tardive dyskinesia and sudden cardiac death.
AstraZeneca has been sued by the U.S. (resulting from a Qui Tam lawsuit filed by Stefan P. Kruszewski) government over the marketing of quetiapine. A $520 million settlement was reached on October 29, 2009.
In 2004, a young man named Dan Markingson committed suicide in a controversial Seroquel clinical trial at the University of Minnesota while under an involuntary commitment order. A group of University of Minnesota bioethicists charged that the trial involved an alarming number of ethical violations, but the university declined to investigate.
Several American soldiers and veterans have died while taking Seroquel for PTSD.
Multiple lawsuits have been filed in relation to quetiapine's side-effects, in particular, diabetes.
In Australia, Professor Patrick McGorry, a key mental health adviser proposed a trial in Melbourne in 2011. It was to investigate whether Seroquel would decrease or delay the risk of people aged between 15 and 40 with early signs of mental illness, developing a later psychotic disorder. However in July 2011 psychiatrists, psychologists and researchers from Australia, New Zealand, Canada, Britain and the US lodged a complaint with the ethics committee of Melbourne Health. They opposed the trial as "unethical" and "dangerous".
In 2009, documents unsealed in litigation against AstraZeneca indicated that Dr. Charles Schulz, Chair of the Department of Psychiatry at the University of Minnesota and a consultant for AstraZeneca, had misrepresented the benefits of Seroquel in research presentations and press releases.
Quetiapine is not classified as a controlled substance, "abusive self-administration seems to be driven by quetiapine’s sedative and anxiolytic effects (to help with sleep or to 'calm down') rather than by its antipsychotic properties." Reports of quetiapine abuse have emerged in the medical literature. In addition to oral administration, the drug is also taken intranasally by snorting pulverized tablets (insufflation). There have been reports of intravenous abuse and intravenous co-administration with cocaine as well. This is commonly referred to as a "Q-Ball". A 2004 letter to the editor of the American Journal of Psychiatry provided an anecdotal estimate that up to 30% of inmates who were seen for psychiatric services in the Los Angeles County Jail were faking psychotic symptoms in an attempt to obtain quetiapine. Also known as "quell", "Snoozeberries", or "Susie-Q", the drug may be more commonly abused in prisons due to its capacity to be regularly prescribed as a sedative and the unavailability in prison of more commonly abused substances. A letter to the editor that appeared in the January 2007 American Journal of Psychiatry has proposed a “need for additional studies to explore the addiction-potential of quetiapine”. The letter reports that its authors are physicians who work in the Ohio correctional system. They report that “prisoners ... have threatened legal action and even suicide when presented with discontinuation of quetiapine” and that they have “not seen similar drug-seeking behavior with other second-generation antipsychotics of comparable efficacy”. It has also been reported that when Seroquel is used with methadone it causes the user to experience a buzz, or opioid euphoria.
Nurofen Plus tampering case
In August 2011 the UK's Medicines and Healthcare products Regulatory Agency (MHRA) issued a class 4 drug alert following reports that some batches of Nurofen plus contained Seroquel XL instead.
Following the issue of the Class 4 Drug Alert, Reckitt Benckiser (UK) Ltd received further reports of rogue blister strips in cartons of two additional batches of Nurofen Plus tablets. One of the new batches contained Seroquel XL 50 mg tablets and one contained the Pfizer product Neurontin 100 mg capsules.
Following discussions with the MHRA's Defective Medicines Report Centre (DMRC), Reckitt Benckiser (UK) Ltd decided to recall all remaining unexpired stock of Nurofen Plus tablets in any pack size leading to a Class 1 Drug Alert. The contamination was later traced to in store tampering by a customer.
- ^ a b "SEROQUEL". Drug Patent Watch. thinkBiotech LLC. Retrieved 9 July 2012.
- ^ "Novel dibenzothiazepine antipsychotic". US Patent & Trademark Office, Patent Full Text and Image Database. US Patent and Trademark Office. 7. Retrieved 9 July 2012.
- ^ "Blockbuster Drugs That Will Go Generic Soon - The Best Life (usnews.com)". Money.usnews.com. 2011-04-29. Retrieved 2012-07-09.
- ^ "Quepin Full Prescribing Information in Drug Reference Encyclopedia". Retrieved 2010-04-03.
- ^ "quetiapine-fumarate". The American Society of Health-System Pharmacists. Retrieved 3 April 2011.
- ^ a b c "Pharmaceutical Giant AstraZeneca to Pay $520 Million for Off-label Drug Marketing". Justice news, US Department of Justice. Retrieved 2012-07-16.
- ^ Guzman, F. "Quetiapine Indications: FDA-Approved and Off-label Uses". Psychopharmacology Institute. Retrieved 19 January 2013.
- ^ Kane JM, Correll CU. Pharmacologic treatment of schizophrenia. Dialogues Clin Neurosci. 2010;12(3):345–57. PMID 20954430.
- ^ Schultz SH, North SW, Shields CG. Schizophrenia: a review. Am Fam Physician. 2007;75(12):1821–9. PMID 17619525.
- ^ Thase, M. E.; MacFadden, W.; Weisler, R. H.; Chang, W.; Paulsson, B. ?R.; Khan, A.; Calabrese, J. R.; Bolder Ii Study, G. (2006). "Efficacy of Quetiapine Monotherapy in Bipolar I and II Depression". Journal of Clinical Psychopharmacology 26 (6): 600. doi:10.1097/01.jcp.0000248603.76231.b7. PMID 17110817.
- ^ Ballard, C.; Margallo-Lana, M.; Juszczak, E.; Douglas, S.; Swann, A.; Thomas, A.; O'Brien, J.; Everratt, A. et al. (2005). "Quetiapine and rivastigmine and cognitive decline in Alzheimer's disease: randomised double blind placebo controlled trial". BMJ 330 (7496): 874. doi:10.1136/bmj.38369.459988.8F. PMC 556156. PMID 15722369.
- ^ Croissant, B.; Klein, O.; Gehrlein, L.; Kniest, A.; Hermann, D.; Diehl, A.; Mann, K. (2006). "Quetiapine in relapse prevention in alcoholics suffering from craving and affective symptoms: a case series". European Psychiatry 21 (8): 570. doi:10.1016/j.eurpsy.2006.04.007. PMID 17161284.
- ^ Mukaddes, N. M.; Abali, O. (2003). "Quetiapine Treatment of Children and Adolescents with Tourette's Disorder". Journal of Child and Adolescent Psychopharmacology 13 (3): 295. doi:10.1089/104454603322572624. PMID 14642017.
- ^ Oliver Sacks "Musicophilia" Knopf NY 2007 P.67
- ^ Becker, P. M. (2006). "Treatment of sleep dysfunction and psychiatric disorders". Current Treatment Options in Neurology 8 (5): 367–375. doi:10.1007/s11940-006-0026-6. PMID 16901376.
- ^ a b AstraZeneca. Seroquel (quietapine fumarate) tablets (PDF). 276521. Retrieved 2013-03-09.
- ^ http://www1.astrazeneca-us.com/pi/Seroquel.pdf
- ^ AlterNet / By Martha Rosenberg (2010-03-06). "Are Veterans Being Given Deadly Cocktails to Treat PTSD? | World". AlterNet. Retrieved 2012-07-09.
- ^ "Questions loom over drug for sleepless vets - Marine Corps News | News from Afghanistan & Iraq". Marine Corps Times. Retrieved 2012-07-09.
- ^ "Unsafe Drugs - Seroquel - Information on AstraZeneca's Psychotropic Medication Seroquel. Seroquel Serious Side Effects Including for People with Diabetes, History of High Blood Sugar and Obesity". Seroquel.legalview.com. Retrieved 2012-07-09.
- ^ By DUFF WILSON Published: July 18, 2011 (2011-07-19). "Heart Warning Added to Label on Popular Antipsychotic Drug". NyTimes. Retrieved 2012-07-09.
- ^ "Seroquel linked to deadly side-effects". Defending The Consumer. Retrieved 2012-07-09.
- ^ "Attorney Bob Goldwater, Robert Goldwater, Seroquel Side Effects". Bobgoldwaterattorney-seroquel.com. Retrieved 2012-07-09.
- ^ "Seroquel & Diabetes Pancreatitis side effects, Lawsuit". Resource4thepeople.com. Retrieved 2012-07-09.
- ^ Shankar Vedantam (2009-03-18). "A Silenced Drug Study Creates An Uproar". The Washington Post.
- ^ a b Correll, CU; Schenk, EM (2008 Mar). "Tardive dyskinesia and new antipsychotics.". Current opinion in psychiatry 21 (2): 151–6. doi:10.1097/YCO.0b013e3282f53132. PMID 18332662.
- ^ Aia P.G. (2011). "Tardive Dyskinesia". Current treatment options in neurology 13 (3): 231–241.
- ^ Antipsychotic-Induced Weight Gain: A Comprehensive Research Synthesis Am J Psychiatry 1999;156:1686-1696.
- ^ Seroquel website
- ^ Seroquel Prescribing Information
- ^ Tiihonen, J.; Lönnqvist, J.; Wahlbeck, K.; Klaukka, T.; Niskanen, L.; Tanskanen, A.; Haukka, J. (2009). "11-year follow-up of mortality in patients with schizophrenia: a population-based cohort study (FIN11 study)" (PDF). The Lancet 374: 620–627. doi:10.1016/S0140-6736(09)60742-X.
- ^ a b Group, BMJ, ed. (March 2009). "4.2.1". British National Formulary (57 ed.). United Kingdom: Royal Pharmaceutical Society of Great Britain. p. 192. ISBN 0260-535X. "Withdrawal of antipsychotic drugs after long-term therapy should always be gradual and closely monitored to avoid the risk of acute withdrawal syndromes or rapid relapse."
- ^ a b Kim, DR.; Staab, JP. (May 2005). "Quetiapine discontinuation syndrome". Am J Psychiatry 162 (5): 1020. doi:10.1176/appi.ajp.162.5.1020. PMID 15863814.
- ^ Michaelides, C.; Thakore-James, M.; Durso, R. (Jun 2005). "Reversible withdrawal dyskinesia associated with quetiapine". Mov Disord 20 (6): 769–70. doi:10.1002/mds.20427. PMID 15747370.
- ^ Chouinard, G.; Jones, BD. (Jan 1980). "Neuroleptic-induced supersensitivity psychosis: clinical and pharmacologic characteristics". Am J Psychiatry 137 (1): 16–21. PMID 6101522.
- ^ Miller, R.; Chouinard, G. (Nov 1993). "Loss of striatal cholinergic neurons as a basis for tardive and L-dopa-induced dyskinesias, neuroleptic-induced supersensitivity psychosis and refractory schizophrenia". Biol Psychiatry 34 (10): 713–38. PMID 7904833.
- ^ Chouinard, G.; Jones, BD.; Annable, L. (Nov 1978). "Neuroleptic-induced supersensitivity psychosis". Am J Psychiatry 135 (11): 1409–10. PMID 30291.
- ^ Seeman, P.; Weinshenker, D.; Quiron, R.; Srivastava, LK.; Bhardwaj, SK.; Grandy, DK.; Premont, RT.; Sotnikova, TD.; Boksa, P.; El-Ghundi, M.; O'dowd, BF.; George, SR.; Perreault, ML.; Mannisto, PT; Robinson, S.; Palmiter, RD.; Tallerico, T. (Mar 2005). "Dopamine supersensitivity correlates with D2High states, implying many paths to psychosis". Proc Natl Acad Sci U S A 102 (9): 3513–8. doi:10.1073/pnas.0409766102. PMC 548961. PMID 15716360.
- ^ Moncrieff, J. (Jul 2006). "Does antipsychotic withdrawal provoke psychosis? Review of the literature on rapid onset psychosis (supersensitivity psychosis) and withdrawal-related relapse". Acta Psychiatr Scand 114 (1): 3–13. doi:10.1111/j.1600-0447.2006.00787.x. PMID 16774655.
- ^ R. Baselt, Disposition of Toxic Drugs and Chemicals in Man, 8th edition, Biomedical Publications, Foster City, CA, 2008, pp. 1355–1357.
- ^ "QUEtiapine". Hudson, OH: Lexi-Comp. 2012. Retrieved 18 October 2012.
- ^ AstraZeneca Pharmaceuticals LP (March 2011). "SEROQUEL (quetiapine fumarate) tablet, extended release". DailyMed. National Library of Medicine. Section 12.2: Pharmacodynamics. Retrieved 2011-04-26.
- ^ Richelson E, Souder T (November 2000). "Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds". Life Sciences 68 (1): 29–39. doi:10.1016/S0024-3205(00)00911-5. PMID 11132243.
- ^ Davis, Kenneth L; Neuropsychopharmacology, American College of (2002). Neuropsychopharmacology: the fifth ... - Google Books. ISBN 978-0-7817-2837-9.
- ^ "Seroquel Official FDA information, side effects and uses". Drugs.com. Retrieved 2012-07-09.
- ^ Guzman, F. "Mechanism of action of quetiapine". Psychopharmacology Institute. Retrieved 20 January 2013.
- ^ Kapur, S.; Seeman, P (2001). "Does fast dissociation from the dopamine d(2) receptor explain the action of atypical antipsychotics?:a new hypothesis". American Journal of Psychiatry 158 (3): 360–369. doi:10.1176/appi.ajp.158.3.360. PMID 11229973.
- ^ Seeman P (2002). "Atypical antipsychotics: mechanism of action". Can J Psychiatry 47 (1): 27–38. PMID 11873706.
- ^ Warawa, E. J.; Migler, B. M.; 1988, U.S. Patent 4,879,288.
- ^ E. Richelson and T. Souder (November 2000). "Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds". Life Sciences 68 (1): 29–39. doi:10.1016/S0024-3205(00)00911-5. PMID 11132243.
- ^ O Gefvert, T Lundberga, I-M Wieselgrenb, M Bergströmc, B Långströmc, F-A Wieselb and L Lindström (April 2001). "D2 and 5HT2A receptor occupancy of different doses of quetiapine in schizophrenia: a PET study". European Neuropsychopharmacology 11 (2): 105–110. doi:10.1016/S0924-977X(00)00133-4. PMID 11313155.
- ^ Oregon State University Drug Use Evaluation: Low-Dose Quetiapine (Seroquel, Seroquel XR) PDF
- ^ "AstraZeneca Submits an NDA For Sustained Release Formulation Seroquel XR. For the treatment of schizophrenia." (Press release). AstraZeneca. 2006-07-18. http://www.astrazeneca.com/pressrelease/5256.aspx. Retrieved 2007-01-01.
- ^ "AstraZeneca Submits EU and Canadian Regulatory Filings for Sustained Release Formulation SEROQUEL XR for the Treatment of Schizophrenia" (Press release). AstraZeneca. 2006-10-19. http://www.astrazeneca.com/pressrelease/5275.aspx. Retrieved 2007-01-01.
- ^ "FDA Approves AstraZeneca’s Once-Daily SEROQUEL XR Extended-Release Tablets For The Treatment Of Schizophrenia" (Press release). AstraZeneca. 2007-05-18. http://www.astrazeneca.com/pressrelease/5330.aspx. Retrieved 2007-08-02.
- ^ "Second Quarter and Half Year Results 2007" (Press release). AstraZeneca. 2007-07-26. http://www.astrazeneca.com/pressrelease/5341.aspx. Retrieved 2007-08-02.
- ^ "Seroquel XR Receives Approval from FDA for Maintenance Treatment of Schizophrenia" (Press release). AstraZeneca. 2007-11-16. http://www.astrazeneca.com/pressrelease/5360.aspx. Retrieved 2007-12-03.
- ^ Notice of Compliance Information - Seroquel XR September 27, 2007, retrieved December 3, 2007
- ^ "Biovail Announces Filing of ANDA for Quetiapine XR Tablets" (Press release). Biovail. 2008-12-28. http://www.biovail.com/english/Investor%20Relations/Latest%20News/default.asp?s=1&state=showrelease&releaseid=1230930.
- ^ "AstraZeneca Receives FDA Complete Response Letter on Seroquel XR for Major Depressive Disorder" (Press release). AstraZeneca. 2008-12-24. http://www.astrazeneca.com/media/latest-press-releases/seroquel-MDD-FDA-response?itemId=4477598. Retrieved 2008-12-28.
- ^ "QUETIAPINE FUMARATE". Electronic Orange Book. Food and Drug Administration. April 2007. Retrieved 2007-05-24.
- ^ "AstraZeneca Receives FDA Approval for SEROQUEL in Bipolar Mania" (Press release). AstraZeneca. 2004-01-13. http://www.prnewswire.co.uk/cgi/news/release?id=115109.
- ^ "April 7–8, 2009: Psychopharmacologic Drugs Advisory Committee Meeting Announcement". Retrieved 2009-08-27.
- ^ Wilson, Duff (2009-10-29). "AstraZeneca Pays Millions to Settle Seroquel Cases". New York Times. Retrieved 2010-03-09.
- ^ Elliott, Carl (September–October 2010). "The Deadly Corruption of Clinical Trials". Mother Jones. Retrieved 2 December 2012.
- ^ Couzin-Frankel, Jennifer (December 7, 2010). "Minnesota bioethicists critique their university". Science. Retrieved 2 December 2012.
- ^ Matthew Perrone (August 30, 2010). "Questions loom over drug given to sleepless vets". Associate Press. Retrieved November 28, 2010.
- ^ Ann Knef (2007-08-02). "Seroquel suit claims 'so much' is poured into marketing and away from research". The Madison / St. Clair Record.
- ^ Phil Milford (2009-03-11). "AstraZeneca May Link Seroquel, Diabetes, Doctor Says". Bloomberg.com (Bloomberg L.P.).
- ^ March 19, 2010 (2010-03-19). "AstraZeneca wins bellwether Seroquel case". FiercePharma. Retrieved 2012-07-09.
- ^ "AstraZeneca pays out million dollar damages". The Local. 2010-08-09.
- ^ Sydney Morning Herald
- ^ Maura Lerner and Janet Moore (March 19, 2009). "Once-secret drug-company records put U on the spot". Minneapolis Star Tribune. Retrieved 2 December 2012.
- ^ Joseph M. Pierre, M.D., Igor Shnayder, M.D., Donna A. Wirshing, M.D., and William C. Wirshing, M.D. "Intranasal Quetiapine Abuse". American Psychiatric Association.
- ^ a b Brian M. Waters and Kaustubh G. Joshi (January 2007). "Intravenous Quetiapine-Cocaine Use ("Q-Ball")". Am J Psychiatry (American Psychiatric Association) 164 (1): 173–a–174. doi:10.1176/appi.ajp.164.1.173-a. PMID 17202567.
- ^ Joseph M. Pierre, Igor Shnayder, Donna A. Wirshing, and William Wirshing (September 2004). "Intranasal Quetiapine Abuse". Am J Psychiatry (American Psychiatric Association) 161 (9): 1718. doi:10.1176/appi.ajp.161.9.1718. PMID 15337673.
- ^ Pinta, E. R.; Taylor, R. E. (2007). "Quetiapine Addiction?". American Journal of Psychiatry 164 (1): 174. doi:10.1176/appi.ajp.164.1.174. PMID 17202569.
- ^ "Press releases". MHRA. Retrieved 2012-07-09.
- ^ "Drug Alerts". MHRA. Retrieved 2012-07-09.
- ^ "BBC News - Nurofen Plus tampering: Christopher McGuire jailed". Bbc.co.uk. 2012-05-28. Retrieved 2012-07-09.
- Agonists: 77-LH-28-1
- SDZ 210-086
Antagonists: 3-Quinuclidinyl Benzilate
- Aclidinium Bromide
- Atropine Methonitrate
- BIBN 99
- Ipratropium bromide
- Mamba Toxin 3
- Mamba Toxin 7
- N-Ethyl-3-Piperidyl Benzilate
- N-Methyl-3-Piperidyl Benzilate
- Tiotropium bromide
- Zamifenacin; Others: 1st Generation Antihistamines (Brompheniramine
- triprolidine, etc)
- Tricyclic Antidepressants (Amitriptyline
- trimipramine, etc)
- Tetracyclic Antidepressants (Amoxapine
- maprotiline, etc)
- Typical Antipsychotics (Chlorpromazine
- thioridazine, etc)
- Atypical Antipsychotics (Clozapine
- olanzapine, etc.)
- Agonists: 5-HIAA
- Sazetidine A
- Kynurenic acid
- Methadone (Levomethadone)
- Nitrous Oxide
- Adamantanes: Amantadine
- Rimantadine; Aminotetralins: 7-OH-DPAT
- UH-232; Benzazepines: 6-Br-APB
- SKF-83,959; Ergolines: Bromocriptine
- Pergolide; Dihydrexidine derivatives: 2-OH-NPA
- Doxanthrine; Others: A-68,930
- Salvinorin A
- Ungrouped: Belarizine
- Miscellaneous: Tricyclic antidepressants (amitriptyline,
- trimipramine, etc)
- Tetracyclic antidepressants (mianserin,
- mirtazapine, etc)
- Typical antipsychotics (chlorpromazine,
- thioridazine, etc)
- Atypical antipsychotics (clozapine,
- quetiapine, etc)
- Agonists: Azapirones: Alnespirone
- Zalospirone; Antidepressants: Etoperidone
- Vortioxetine; Antipsychotics: Aripiprazole
- Ziprasidone; Ergolines: Dihydroergotamine
- LSD; Tryptamines: 5-CT
- Psilocybin; Others: 8-OH-DPAT
- Bay R 1531
- S 14,506
Antagonists: Antipsychotics: Iloperidone
- Sertindole; Beta blockers: Alprenolol
- Tertatolol; Others: AV965
- SDZ 216-525
- Agonists: Lysergamides: Dihydroergotamine
- Methysergide; Triptans: Almotriptan
- Zolmitriptan; Tryptamines: 5-CT
- 5-(Nonyloxy)tryptamine; Others: CP-135,807
Antagonists: Lysergamides: Metergoline; Others: Alniditan
- Agonists: Phenethylamines: 2C-B
- Mescaline; Piperazines: Aripiprazole
- TFMPP; Tryptamines: 5-CT
- Psilocybin; Others: A-372,159
- Org 12,962
Antagonists: Atypical antipsychotics: Clorotepine
- Zotepine; Typical antipsychotics: Chlorpromazine
- Pipamperone; Antidepressants: Agomelatine
- Trazodone; Others: Adatanserin
- SDZ SER-082
- Agonists: Lysergamides: Dihydroergotamine
- Methysergide; Tryptamines: 2-Methyl-5-HT
- Tryptamine; Others: WAY-181,187
Antagonists: Antidepressants: Amitriptyline
- Nortriptyline; Atypical antipsychotics: Aripiprazole
- Tiospirone; Typical antipsychotics: Chlorpromazine
- Loxapine; Others: BGC20-760
- Lu AE58054
- Ro 63-0563
- Agonists: Lysergamides: LSD; Tryptamines: 5-CT
- Bufotenin; Others: 8-OH-DPAT
Antagonists: Lysergamides: 2-Bromo-LSD
- Methysergide; Antidepressants: Amitriptyline
- Mianserin; Atypical antipsychotics: Amisulpride
- Zotepine; Typical antipsychotics: Chlorpromazine
- Loxapine; Others: Butaclamol